Pre-operative Treatment With Erythropoietin and Iron Supplement for Prevention of Perioperative Blood Transfusion in Cardiac Surgery

NCT02210949 Phase 4 TERMINATED

Pre-treatment of patients with erythropoietin subcutaneously and iron supplement intravenously, in order to create a clinical pathway to minimize transfusion of red blood cells in a selected group of cardiac patients with an increased risk for blood transfusions in our cardiac surgery program.

Details

Lead sponsor	Catharina Ziekenhuis Eindhoven
Phase	Phase 4
Status	TERMINATED
Enrolment	7
Start date	2014-08
Completion	2017-04

Conditions

• Heart; Dysfunction Postoperative, Cardiac Surgery
• Anemia, Iron-Deficiency

Interventions

• Erythropoietin subcutaneously and Iron intravenously

Primary outcomes

• The number of patients who receive RBC transfusion perioperatively — 1 day
  To determine the reduction of the number of patients receiving blood transfusion the pre-treated group with erythropoietin and iron supplement compared to the control patients.
• The number of patients who receive RBC transfusion perioperatively — 3 days
  To determine the reduction of the number of patients receiving blood transfusion the pre-treated group with erythropoietin and iron supplement compared to the control patients.
• The number of patients who receive RBC transfusion perioperatively — 30 days
  To determine the reduction of the number of patients receiving blood transfusion the pre-treated group with erythropoietin and iron supplement compared to the control patients.

Countries

Netherlands